10
M. Pazos et al. / Tetrahedron: Asymmetry xxx (2015) xxx–xxx
(s, 3H), 1.26 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) d 171.3,
135.8, 128.3, 109.6, 80.6, 75.5, 73.1, 70.5, 61.1, 39.0, 25.6, 25.3,
21.3, 14.2; IR (cmÀ1) = 2980, 2936, 2899, 1759, 1726, 1205, 1173,
1063; MS (EI, 70 eV) m/z (rel. int.): 73.05 (100), 81.10 (44), 97.10
(70), 256.20 (20); HRMS (ESI+) calcd for C14H20O5 = 291.1203 (M
sulphonylisocyanate) (final p-toluenesulphonylisocyanate concen-
tration = 2 M). The mixture was heated at reflux for 4.5 h, after
which it was cooled to 50 °C and used without any purification
to the cycloaddition reaction. A 0.5 M solution of the correspond-
ing diene in dry toluene was added to the freshly prepared N-tosyl
imine. The mixture was heated at reflux until the starting material
was consumed. The system was allowed to reach room tempera-
ture. Toluene was removed in vacuo and product was purified by
chromatographic column using SiO2 as the stationary phase.
+Na+) found 291.1277; [
a
]
D
21 = À51 (c 0.9, MeOH).
4.3.2.2. (1S,3S,4R,7R,8S)-Ethyl 7,8-isopropylidenedioxy-1-methyl-
2-oxabicycle[2.2.2]-5-octen-3-carboxylate exo-7.
1H NMR
(500 MHz, CDCl3) d (ppm) = 6.34 (ddd, J = 8.0, 6.7, 0.9 Hz, 1H),
6.10 (ddd, J = 8.0, 1.1, 1.1 Hz, 1H), 4.30–4.16 (m, 4H), 3.86 (d,
J = 2.0 Hz, 1H), 3.37–3.33 (ddt, J = 7.0, 3.6, 1.7 Hz 1H), 1.56 (s,
3H), 1.32–1.23 (m, 9H); 13C NMR (125 MHz, CDCl3) d 171.3,
134.9, 131.0, 109.0, 80.2, 73.7, 72.8, 71.8, 61.3, 38.3, 25.6, 25.2,
21.2, 14.2.
4.3.3.1. (1S,4S,7R,8S)-Ethyl 7,8-isopropylidendioxy-1-methyl-2-
tosyl-2-azabicycle[2.2.2]5-octenen-3-carboxylate exo and endo-
6. exo-Isomer: 1H NMR (400 MHz, CDCl3): d(ppm) = 7.96 (dt,
J = 1.9, 8.3 Hz, 2H), 7.30 (d, J = 8.2 Hz, 2H); 6.22 ddd, J = 0.9, 6.7,
8.0 Hz, 1H), 5.96 (dt, J = 1.1, 8.1 Hz, 1H), 4.36 (ddd, J = 0.7, 3.5,
7.1 Hz, 1H), 4.31 (q, J = 7.2 Hz, 2H), 4.24 (d, J = 3.3 Hz, 1H), 4.16
(dd, J = 0.9, 7.1 Hz, 1H), 3.40 (dddd, J = 1.2, 3.4, 3.4, 6.7 Hz, 1H),
2.42 (s, 3H), 1.44 (s, 3H), 1.35 (t, J = 7.2 Hz, 3H), 1.25 (s, 3H), 1,23
(s, 3H); 13C NMR (100 MHz, CDCl3): d(ppm) = 170.7, 135.7, 129.5,
128.0, 110.0, 81.0, 73.6, 61.7, 58.9, 58.7, 37.6, 25.5, 25.3, 21.6,
19.2, 14.2; endo-isomer: 1H NMR (400 MHz, CDCl3): d(ppm)
= 8.09 (dt, J = 1.9, 8.3 Hz, 2H), 7.30–7.28 (m, 2H); 6.07 (ddd,
J = 0.9, 6.4, 7.6 Hz, 1H), 5.91 (ddd, J = 1.0, 1.6, 8.0 Hz, 1H), 4.60 (d,
J = 2.4 Hz, 1H), 4.58 (dd, J = 1.0, 7.1 Hz, 1H), 4.53 (ddd, J = 1.0, 3.3,
7.1 Hz, 1H), 4.25–4.23 (dd, J = 0.9, 7.1 Hz, 1H), 3.52–4.48 (m, 1H),
2.42 (s, 3H), 1.39 (s, 3H) 1.32–1.27 (m, 9H); 13C NMR (100 MHz,
CDCl3): d(ppm) = 170.72, 143.49, 140.28, 136.43, 129.56, 129.46,
128.13, 109.64, 79.07, 76.04, 61.48, 58.78, 56.27, 39.75, 29.69,
26.90, 25.48, 22.66, 19.23; IR (/cm): 2986, 2937, 1746, 1375,
1118, 712; MS: m/z (Int. Rel) = 65.1 (22); 91.1 (98); 155.1 (58);
248.1 (100); 406.1 (6); HRMS (ESI+) calcd for C21H27NO6-
SNa = 444.1457 (M+Na+) found 444.1451.
4.3.2.3. (1S,3S,4R,7S,8S)-Ethyl 7,8-isopropylidenedioxy-1-propil-
2-oxabicycle[2.2.2]-5-octen-3-carboxylate 8. 1H NMR (400 MHz,
CDCl3) d (ppm) = 6.19 (d, J = 8.4 Hz, 1H), 6.11 (dd, J = 8.4, 6.3 Hz,
1H), 4.39 (dd, J = 7.1, 3.5, 1.0 Hz, 1H), 4.17–4.06 (m, 3H), 3.43
(ddd, J = 7.3, 3.5, 1.7 Hz, 1H), 1.33 (s, 3H), 1.95 (ddd, J = 14.2,
11.8, 4,9 Hz, 3H), 1.71 (d, J = 4.6 Hz, 1H), 1.73–1.66 (m, 1H), 1.66–
1.59 (m, 1H), 1.57–1.49 (m, 1H), 1.28 (s, 3H), 1.27 (s, 3H), 1.23 (t,
J = 7.1 Hz, 3H) 0.98 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3)
d (ppm) = 171.4, 134.3, 128.5, 109.5, 79.7, 75.6, 75.4, 70.3, 60.9,
38.9, 36.9, 25.6, 25.2, 16.5, 14.5, 14.1; IR (cmÀ1): 2978, 2961,
2936, 2911, 2876, 1759, 1728, 1373, 1207, 1165, 1072, 1030; MS
(EI, 70 eV) m/z (%): 91.10 (44), 123.15 (100), 165.10 (84), 295
(M+, 16); [
a
]
D
21 = À7.4 (c 1.1, MeCN).
4.3.2.4. (1S,3S,4R,7S,8S)-Ethyl-7,8-isopropylidenedioxy-1-(ace-
toxymethyl)-2-oxabicyclo[2.2.2]-5-octen-3-carboxylate 9. 1H
NMR (400 MHz, CDCl3) d (ppm) = 6.16 (d, J = 1.4 Hz, 1H), 6.15
(dd, J = 1.8, 1.1 Hz, 1H), 4.52 (dd, J = 12.2, 1.5 Hz, 1H), 4.42 (ddd,
J = 7.1, 3.0, 1.0 Hz, 1H), 4.31 (dd, J = 12.2, 1.4 Hz, 1H), 4.27 (dd,
J = 7.1, 1.1 Hz, 1H), 4.17 (t, J = 1.6 Hz, 1H), 4.11 (ddd, J = 7.1, 6.5,
1.6 Hz, 1H), 3.47 (dtd, J = 6.4, 3.4, 1.7 Hz, 1H), 2.10–2.09 (m, 3H),
2.08–1.99 (m, 1H), 1.25 (t, J = 1.5 Hz, 6H), 1.20 (td, J = 7.1, 1.6 Hz,
3H); 13C NMR (100 MHz, CDCl3) d (ppm) = 170.8, 170.7, 131.4,
129.2, 110.1, 75.9, 75.0, 74.2, 70.0, 64.6, 61.1, 39.6, 25.5, 25.2,
20.8, 14.1; IR (cmÀ1): 2984, 2937, 1748, 1242, 1209, 1057; MS
(EI, 70 eV) m/z (rel. int.): 107.1 (70), 153.1 (100), 195.1 (72),
208.1 (51), 212.1 (M+, 51); HRMS (ESI+) calcd for C14H20O5-
4.3.3.2. (1S,4S,7R,8S)-Ethyl 7,8-isopropylidendioxy-1-propyl-
2-tosyl-2-azabicyclo[2.2.2]5-octene-3-carboxylate 10 exo- and
endo-10. exo-isomer: 1H NMR (400 MHz, CDCl3) d (ppm) = 7.84
(ddd, J = 8.4, 2.1, 1.8 Hz, 2H), 7.33–7.29 (m, 2H), 6.04 (ddd, J = 1.2,
7.0, 7.9 Hz, 1H), 5.82 (dt, J = 1.0, 8.0 Hz, 1H), 4.43 (dd, J = 7.0,
1.0 Hz, 1H), 4.34–4.28 (m, 3H), 4.17 (d, J = 3.5 Hz, 2H), 3.37 (dddd,
J = 6.9, 3.5, 3.5, 1.2 Hz, 1H), 2.44 (s, 3H), 2.23–2.14 (m, 1H), 2.03–
1.91 (m, 1H), 1.50–1.40 (m, 2H), 1.27 (s, 3H), 1.26 (t, J = 7.2 Hz,
3H);13C NMR (100 MHz, CDCl3) d (ppm) = 172.1, 170.6, 131.1,
129.8, 111.4, 84.4, 77.4, 77.0, 76.7, 76.1, 69.6, 68.4, 61.4, 53.0,
38.8, 25.9, 25.7, 14.2.; endo-isomer: 1H NMR (400 MHz, CDCl3) d
(ppm) = 8.02 (ddd, J = 8.4, 2.1, 1.9 Hz, 2H), 7.34–7.29 (m, 2H),
6.12 (s, 1H), 6.11 (s, 1H), 4.65 (d, J = 2.9 Hz, 1H), 4.62 (d,
J = 6.8 Hz, 1H), 4.42 (d, J = 7.0, 3.3 Hz, 1H), 4.16–4.11 (m, 2H),
3.50 (m, 1H), 2.44 (s, 3H), 2.23–2.14 (m, 1H), 2.03–1.91 (m, 1H),
1.50–1.40 (m, 2H), 1.27 (s, 3H), 1.26 (t, J = 7.2 Hz, 3H), 1.26–1.24
(m, 3H), 0.67 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) d
(ppm) = 170.6, 133.9, 129.4, 129.3, 128.3, 109.4, 79.1, 75.9, 63.9,
61.7, 57.0, 39.4, 34.6, 34.2, 26.9, 25.0, 21.6, 14.3, 14.1;IR (cmÀ1):
2974, 2937, 1751, 1373, 1352, 1325, 1209, 1180, 1163, 1078,
970, 710, 590, 550; MS (EI, 70 eV) m/z (rel. int.): 91.1 (79), 155.1
(85), 108.1 (35), 236.1 (34), 276.1 (97), 294.2 (37), 318.1 (100);
HRMS (ESI+) calcd for C23H21NO6SNa = 472.1764 (M+Na+) found
472.1764.
Na = 349.1258 (M+Na+) found 349.1334;
MeOH).
[a
]
D
21 = À23.6 (c 1.2,
4.3.2.5. (1S,3S,4S,7R,8S)-3-Ethyl -8-methyl-7,8-isopropylidene-
dioxy-2-oxabicycle[2.2.2]5-octene-3,8-dicarboxylate 14. 1H NMR
(400 MHz, CDCl3) d (ppm) = 6.46 (ddd, J = 7.3, 5.6, 1.5 Hz, 1H),
6.25 (t, J = 7.3 Hz, 1H), 5.02 (d, J = 3.8 Hz, 1H), 4.89 (dd, J = 5.3,
1.3 Hz, 1H), 4.23 (d, J = 1.6 Hz, 1H), 4.18 (dq, J = 7.3, 1.3 Hz, 2H),
3.85 (s, 3H), 3.62 (dddd, J = 6.4, 4.0, 1.7, 1.7 Hz, 1H), 1.33 (s, 3H),
1.27 (s, 3H), 1.26 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) d
(ppm) = 172.1, 170.6, 131.1, 129.8, 111.4, 84.4, 77.4, 77.0, 76.7,
76.1, 69.6, 68.4, 61.4, 53.0, 38.8, 25.9, 25.7, 14.2.; IR (cmÀ1):
2988, 2955, 2940, 1759, 1738, 1375, 1267, 1228, 1211, 1179,
1163, 1113, 1065, 1045, 1026, 897, 872, 856, 725; MS (EI, 70 eV)
m/z (%): 60.05 (73), 73.05 (100), 83.15 (66), 97, 10 (55), 129.15
(54), 213,20 (14); HRMS (ESI+) calcd for C15H20O7 = 335,1090 (M
4.3.3.3. (1R,4S,7R,8S)-Ethyl 1-(acetoxymethyl)-7,8-iopropylidene-
dioxy-2-tosyl-2-azabicycle[2.2.2]5-octen-3-carboxylate 11. 1H
NMR (400 MHz, CDCl3): d (ppm) = 7.93 (d, J = 8.3 Hz, 2H), 7.27–
7.31 (m, 2H), 6.26 (ddd, J = 0.9, 6.7, 8.0 Hz, 1H), 5.95 (dt, J = 1.0,
8.0 Hz; 1H), 4.95 (d, J = 13.0 Hz; 1H), 4.60 (dd, J = 1.0, 7.1 Hz, 2H),
4.28–4.38 (m, 4H), 4.26 (d, J = 12.9 Hz, 1H), 3.49 (dddd, J = 1.2,
3.4, 3.4, 7.0 Hz, 1H), 2.42 (s, 3H), 1.64 (s, 3H), 1.36 (t, J = 7.1 Hz;
3H), 1.23 (s, 6H); 13C NMR (100 MHz, CDCl3): 170.3; 170.2;
+) found 335.1101; [a]
21 = +162 (c 0.5, MeOH).
D
4.3.3. General procedure for the aza Diels–Alder reaction
The ethyl glyoxylate N-tosyl imine 5 was prepared using the
procedure described by Le Goffic et al.29 Ethyl glyoxylate was dis-
solved in dry toluene; followed by p-toluenesulphonyl isocyanate
(1 equiv) and catalytic amounts of AlCl3 (0.5% m/m of p-toluene-